Related Experiment Video
Updated: Dec 27, 2025
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
Published on: July 5, 2019
Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology
Andriy Krendyukov1, Sreekanth Gattu2
1Apogenix AG, VP Global Head Medical Affairs, Im Neuenheimer Feld 584, 69120, Heidelberg, Germany. akrendyukov@gmx.de.
Abstract:
Innovative medicinal products are required to achieve progress in oncology; however, these are associated with high financial investments, extensive development times, and significant risk of potential failure in the pivotal clinical trials required for marketing authorization. With increasing budgetary constraints and requirements to demonstrate value, effective strategies to develop and commercialize innovative oncology products are more important than ever. Strategies that have proved successful in other industries require major revision for use in the oncology field, both during preclinical and clinical development as well as in the post approval value chain. This paper will examine how medicinal product strategy development differs from other industries. In particular, it will look at how the global trend toward value-based healthcare requires strategies that are based on an in-depth scientific understanding of the disease area and product-specific characteristics supported by clinical evidence. The findings are complemented by a review of the available literature and a survey of industry representatives.
Insights
Developing innovative oncology drugs requires revised strategies due to high costs and risks. Value-based healthcare necessitates strategies grounded in scientific understanding and clinical evidence for successful commercialization.
Area of Science:
- Oncology
- Pharmaceutical Development
- Health Economics
Background:
- Innovative oncology medicinal products demand substantial investment, long development timelines, and face high failure risks in clinical trials.
- Budgetary constraints and the need to demonstrate value heighten the importance of effective development and commercialization strategies for oncology products.
Purpose of the Study:
- To examine the unique challenges and strategic differences in developing and commercializing innovative oncology products compared to other industries.
- To analyze how the shift towards value-based healthcare influences medicinal product strategy in oncology.
- To identify key elements for successful oncology product strategy, emphasizing scientific understanding and clinical evidence.
Main Methods:
- Review of existing literature on medicinal product strategy and value-based healthcare.
- Survey of industry representatives involved in oncology drug development and commercialization.
- Analysis of strategic differences between the oncology sector and other industries.
Main Results:
- Standard industry strategies require significant adaptation for the oncology field, spanning preclinical, clinical, and post-approval phases.
- Value-based healthcare mandates strategies deeply rooted in scientific disease understanding and product-specific clinical evidence.
- Successful oncology strategies must integrate scientific rigor with market access and value demonstration.
Conclusions:
- Medicinal product strategy in oncology is distinct due to high R&D costs, regulatory hurdles, and evolving healthcare economics.
- Adapting strategies to align with value-based healthcare principles is crucial for the successful development and commercialization of innovative oncology treatments.
- Future oncology strategies must prioritize a robust scientific foundation, comprehensive clinical evidence, and clear value proposition to navigate market complexities.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
01:27Tumor Immunotherapy
01:11Clinical Trials: Overview